Department of Dermatology and Allergology, University Medical Centre Utrecht, Utrecht, The Netherlands.
J Dermatolog Treat. 2009;20(6):365-7. doi: 10.3109/09546630903085294.
Patients with severe atopic dermatitis (AD) often require treatment with oral immunosuppressive drugs. Everolimus is a rapamycin-derived macrolide with immunosuppressive and antiproliferative effects. Everolimus demonstrated efficacy not only in the prophylaxis of organ rejection in kidney transplant patients, but also in decreasing disease activity in psoriasis patients.
To evaluate whether everolimus is an effective treatment in patients with severe AD.
Two patients with severe AD were treated with everolimus in combination with low-dose cyclosporin A (CsA) or prednisone. During treatment, a disease activity and safety laboratory examination was performed.
Everolimus either in combination with prednisone or with CsA did not result in improvement of disease activity in two patients with severe AD.
Everolimus does not seem to be an effective treatment in these two AD patients, either in combination with prednisone or with CsA.
患有严重特应性皮炎（AD）的患者通常需要接受口服免疫抑制剂治疗。依维莫司是一种具有免疫抑制和抗增殖作用的雷帕霉素衍生的大环内酯类药物。依维莫司不仅在预防肾移植患者的器官排斥方面显示出疗效，而且在降低银屑病患者的疾病活动度方面也显示出疗效。
评估依维莫司是否对严重 AD 患者是一种有效的治疗方法。
对两名患有严重 AD 的患者进行依维莫司联合低剂量环孢素 A（CsA）或泼尼松治疗。在治疗期间，进行了疾病活动和安全性实验室检查。
依维莫司联合泼尼松或 CsA 治疗均未使两名严重 AD 患者的疾病活动得到改善。
依维莫司联合泼尼松或 CsA 治疗似乎对这两名 AD 患者均不是一种有效的治疗方法。
